A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy (PDR), a complication of diabetes that damages blood vessels in the light-sensitive retina in the back of the eye. Lucentis is used to treat wet macular degeneration as well as diabetic macula edema. The study found the treatment no less effective than the laser therapy which currently is the standard treatment for PDR.
In a RPB-supported commentary, Timothy W. Olsen, MD, notes that "this important study [...] represents a major step forward for patients with PDR by providing the ophthalmologists who manage their retinal disease with new options." But he adds a cautionary note.
November 17, 2015
RPB launches awards in data science and Diabetic Eye Disease.
Leaders of organizations that fund vision research convene in Washington DC to increase collaboration and maximize the impact of research funding for sight-threatening diseases.
An RPB grantee makes a key discovery involving genes that are essential for eye health.
RPB funds a new round of researchers and hits a milestone in supporting vision-related breakthroughs.
We welcome your generosity to help us meet our goal!
Dr. Krzysztof Palczewski develops and applies cutting-edge gene editing techniques to challenging genetic conditions.
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
General Info | Grants | News & Resources |